Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 16, Issue 9, Pages 436-442Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2005.09.004
Keywords
-
Categories
Funding
- NIA NIH HHS [R01 AG 19230, R01 AG 18895] Funding Source: Medline
Ask authors/readers for more resources
The spiropiperidine, MK0677, has been exploited to characterize and expression clone the growth hormone secretagogue receptor (GHS-R). Cloning of this receptor led to identification of its natural ligands, ghrelin and adenosine. Targeted disruption of the Ghsr gene demonstrated unambiguously that the GH-releasing and orexigenic properties of ghrelin are dependent on Ghsr expression and that the orexigenic signal is mediated through neuropeptide Y and agouti-related peptide neurons. This review summarizes new developments in our understanding of the physiological roles of ghrelin and its receptor (GHS-R). Recent discoveries of the effects of ghrelin on the thymus and proinflammatory and chemotactic cytokine pathways stimulate renewed interest in potential clinical applications, which include age-associated disorders, such as metabolic disease, sarcopenia, congestive heart failure, atherosclerosis and anorexia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available